April 19 (Reuters) - NICOX SA NCOX.PA :
* PROVIDES FIRST QUARTER 2021 BUSINESS UPDATE AND FINANCIAL
HIGHLIGHTS
* Q1 2021 NET REVENUE OF EUR 0.6 MILLION AND CASH OF EUR
42.0
MILLION AT MARCH 31, 2021
* NCX 470 PHASE 3 TRIALS IN GLAUCOMA ON TRACK FOR TOP-LINE
RESULTS
IN Q2 2022 (MONT BLANC) AND Q4 2022 (DENALI)
* NCX 4251 MISSISSIPPI PHASE 2B TRIAL IN BLEPHARITIS ON
TRACK FOR
TOP-LINE RESULTS IN Q4 2021
* U.S. PRESCRIPTIONS FOR VYZULTA IN Q1 2021INCREASED BY
10.6% OVER
Q1 2020, AND FOR ZERVIATE BY 29.1% OVER Q4 2020
Source text for Eikon: ID:nGNX2NfGXC
Further company coverage: NCOX.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))